[DOI] [PubMed] [Google Scholar] 33.Abdelrazik H, Sharma R, Mahfouz R, Agarwal A
Thus, we suggest that one single application of the NO-synthase (NOS) blocker N(G)-nitro-L-arginine methyl ester (L-NAME) may induce retinal ischemia in rats, and that the stable pentadecapeptide BPC 157 may be the therapy, since it may interact with the NO-system and may counteract various adverse effects of L-NAME application (see Wu et al., 2020) [i.e., activation of the VEGFR2-Akt-eNOS signaling pathway without the need of other known ligands or shear stress ( In the previous eye research studies, BPC 157 counteracts atropine-mydriasis, but it also opposes an immediate and hour-lasting miotic effect of L-NAME in rats and guinea pigs, and participates in pupil control potentially via NO-mediated and cholinergic mechanisms ( This may be essential for the effective counteraction of the damaging effect of the retrobulbar L-NAME application
Elevated results may explain persistent fatigue, poor detox response, or increased reactivity to supplements
It tracks closely with the metabolic deterioration that characterizes the third and fourth decades of life: rising fasting insulin, expanding visceral adipose tissue, declining mitochondrial density in skeletal muscle, and blunted exercise adaptability
